Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun;27(6):299-307.
doi: 10.14744/AnatolJCardiol.2023.3013.

Cancer Therapy-Related Pulmonary Hypertension: A Review of Mechanisms and Implications for Clinical Practice

Muhammet Gürdoğan  1 , Melik Demir  1 , Kenan Yalta  1 , Yekta Gülertop  1
Affiliations
Review

Cancer Therapy-Related Pulmonary Hypertension: A Review of Mechanisms and Implications for Clinical Practice

Muhammet Gürdoğan et al. Anatol J Cardiol. 2023 Jun.

Abstract

Cancer therapy-related pulmonary hypertension is a rare yet potentially fatal cardiotoxicity. However, it is a reversible cause of pulmonary hypertension if detected in its early stages. Cancer therapy-related pulmonary hypertension has been encountered in patients using tyrosine kinase inhibitors, particularly dasatinib. However, it is also well known that many agents used in cancer treatment such as alkylating agents, proteasome inhibitors, thoracic radiation exposure, and immune checkpoint inhibitors are particularly associated with pulmonary hypertension evolution. In case that history, symptoms, and clinical findings suggest a potential cancer therapy-related pulmonary hypertension, echocardiography is considered as the initial tool to detect pulmonary hypertension. If the possibility of pulmonary hypertension is high based on echocardiographic data, cancer treatment, as the initial step, should be discontinued due to its potential risks and other causes for pulmonary hypertension should be investigated thoroughly. Right heart catheterization should be the next step to establish the final diagnosis, and medical management, where appropriate, should be started without delay in these patients according to their pulmonary hypertension subgroup. There exists limited information regarding the diagnostic and management strategies of cancer therapy-related pulmonary hypertension in the current guidelines. In this review article, we aim to present current literature data on the mechanisms and management of cancer therapy-related pulmonary hypertension along with its follow-up algorithm in the setting of cardio-oncology practice.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Current hemodynamic classification for PH. PH, pulmonary hypertension.
Figure 2.
Figure 2.
The place of cancer-treatment-related PH in the current PH grouping. PH, pulmonary hypertension.
Figure 3.
Figure 3.
Follow-up algorithm for CTR-PH. CTR-PH, Cancer therapy-related pulmonary hypertension.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Lyon AR, López-Fernández T, Couch LS, et al. ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229 4361. - PubMed
    1. Herrmann J, Lenihan D, Armenian S, et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J. 2022;43(4):280 299. (10.1093/eurheartj/ehab674) - DOI - PMC - PubMed
    1. Hong JH, Lee SE, Choi SY, et al. Reversible Pulmonary arterial hypertension associated with dasatinib for chronic myeloid leukemia. Cancer Res Treat. 2015;47(4):937 942. (10.4143/crt.2013.155) - DOI - PMC - PubMed
    1. Curigliano G, Lenihan D, Fradley M, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31(2):171 190. (10.1016/j.annonc.2019.10.023) - DOI - PMC - PubMed
    1. Humbert M, Kovacs G, Hoeper MM, et al. ESC/ERS Scientific Document Group. ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;8(26):ehac237.